C4X Discovery Holdings Ltd C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme A potent and selective α4β7 inhibitor with oral bioavailability to support once-daily dosing 22 September 2025 – C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company, today announces the selection of a potential best-in-class pre-clinical candidate from its oral α4β7 integrin inhibitor programme for the treatment of inflammatory bowel disease (IBD). The se ...